N@N

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011

_{//health-fitness.news-articles.net/content/2011/ .. uarter-2011-financial-results-on-may-5-2011.html}
^{Published in Health and Fitness on Tuesday, April 26th 2011 at 6:10 GMT by Market Wire}  

BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its first quarter 2011 financial results on Thursday, May 5, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, May 5, 2011

1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)

• Telephone 888-549-7750 (domestic) or 480-629-9866 (international); conference ID 4435537
• Webcast available at [ http://www.seattlegenetics.com ] in the [ Investors and News section ]

REPLAY access

• Telephone replay will be available beginning at approximately 3:30 p.m. PT on Thursday, May 5, 2011, through 3:30 p.m. PT on Monday, May 9, 2011, by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4435537
• Webcast replay will be available on the Seattle Genetics website at [ http://www.seattlegenetics.com ] in the [ Investors and News section ]

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. In February 2010, the company submitted a Biologics License Application to the U.S. Food and Drug Administration for its lead product candidate, brentuximab vedotin, for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its antibody-drug conjugate (ADC) technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].